uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass. and AMSTERDAM, Dec. 20, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their employment. The equity grants were approved by the Company’s board of directors on December 7, 2022, October 31, 2022, and September 27, 2022 (the “Grant Dates”) each in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate on December 7, 2022, 24 employees received 40,000 restricted stock units (“RSUs”) and options to purchase 26,000 ordinary shares of uniQure. Each option has an exercise price of
Each option has a ten-year term and will vest over four years, with
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com
uniQure Contacts: FOR INVESTORS: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 m.cantor@uniQure.com | Chiara Russo Direct: 617-306-9137 Mobile: 617-306-9137 c.russo@uniQure.com | FOR MEDIA: Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 t.malone@uniQure.com |